Back to Main Menu
Products & Services
Red Blood Cell-Based Liquid Biopsy
One of the major advances in the field of precision cancer treatment is the advent of non-invasive liquid biopsy. Most existing technologies involve the detection of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood plasma. However, a major bottleneck with this approach is that these biomarkers are shed from tumors only at a later stage of the disease. This means that we will miss the chance to detect the disease at its earliest stages, when the chance of effective treatment is the highest.
At MBM, we have developed a Red Blood Cell-based platform, a new approach to liquid biopsy that addresses the inherent problems associated with methods based on ctDNA and CTCs. We are currently performing clinical validation studies on the AccuRed platform in stage I non-small cell lung cancer patients.
Latest Blog Posts
News and healthcare tips
The Often Neglected Red Blood Cell Offers a Breakthrough in Liquid Biopsy Technology for Early Stage Cancer Detection
MBM’s “Colorectal Cancer Recurrence Risk Assessment Marker” announced at the National Colorectal Surgery Symposium
MBM recognized as a Top 30 enterprise in the 2020 National Innovation & Entrepreneurship Competition
Industry leaders gather at Summer Davos to discuss China’s biotechnology revolution